Загрузка...
Efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy in treatment of advanced gastric cancer or gastroesophageal junction cancer: A meta-analysis
BACKGROUND: Faced with limited and inadequate treatment options for patients with advanced gastric cancer or gastroesophageal junction cancer (GC/GEJC), researchers have turned toward, with the support of promising clinical trials, anti-PD-1/anti-PD-L1 antibody therapy. But there are also different...
Сохранить в:
| Опубликовано в: : | World J Gastrointest Oncol |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Baishideng Publishing Group Inc
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7667450/ https://ncbi.nlm.nih.gov/pubmed/33250966 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4251/wjgo.v12.i11.1346 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|